Statement Of Cash Flows [Abstract]

BerGenBio - Filing #2581090

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	—	302,122,000 NOK	302,122,000 NOK	—	309,364,000 NOK	309,364,000 NOK	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for provisions	—	969,000 NOK	—	—	—	5,039,000 NOK	—
Adjustments for unrealised foreign exchange losses (gains)	—	3,280,000 NOK	—	—	—	667,000 NOK	—
Adjustments for share-based payments	—	3,466,000 NOK	—	—	—	7,113,000 NOK	—
Cash flows from (used in) operating activities	—	288,231,000 NOK	—	—	—	303,340,000 NOK	—
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities	—	299,000 NOK	—	—	—	—	—
Interest received, classified as investing activities	—	2,949,000 NOK	—	—	—	3,130,000 NOK	—
Cash flows from (used in) investing activities	—	3,248,000 NOK	—	—	—	3,130,000 NOK	—
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	—	3,218,000 NOK	—	—	—	16,629,000 NOK	—
Payments of lease liabilities, classified as financing activities	—	307,000 NOK	—	—	—	565,000 NOK	—
Cash flows from (used in) financing activities	—	2,904,000 NOK	—	—	—	15,995,000 NOK	—
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes	—	282,080,000 NOK	—	—	—	284,216,000 NOK	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	—	3,764,000 NOK	—	—	—	779,000 NOK	—
Cash and cash equivalents	150,803,000 NOK	—	—	436,646,000 NOK	—	—	721,641,000 NOK